

I thank you for the opportunity to comment on the Draft Guideline Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs) (previously called "Guidance on Investigational Medicinal Products (IMPS) and Non-Investigational Medicinal Products (NIMPs)).

After consulting the IPFA member organisations I can inform you that we have no comments on this draft document.